<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nguyen, Dung</style></author><author><style face="normal" font="default" size="100%">Peter Simmonds</style></author><author><style face="normal" font="default" size="100%">Maurice Steenhuis</style></author><author><style face="normal" font="default" size="100%">Elise Wouters</style></author><author><style face="normal" font="default" size="100%">Desmecht, Daniel</style></author><author><style face="normal" font="default" size="100%">Mutien Garigliany</style></author><author><style face="normal" font="default" size="100%">Marta Romano</style></author><author><style face="normal" font="default" size="100%">Cyril Barbezange</style></author><author><style face="normal" font="default" size="100%">Piet Maes</style></author><author><style face="normal" font="default" size="100%">Bram Van Holm</style></author><author><style face="normal" font="default" size="100%">Joaquín Mendoza</style></author><author><style face="normal" font="default" size="100%">Salvador Oyonarte</style></author><author><style face="normal" font="default" size="100%">Anders Fomsgaard</style></author><author><style face="normal" font="default" size="100%">Ria Lassaunière</style></author><author><style face="normal" font="default" size="100%">Eva Zusinaite</style></author><author><style face="normal" font="default" size="100%">Katarina Resman Rus</style></author><author><style face="normal" font="default" size="100%">Tatjana Avšič-Županc</style></author><author><style face="normal" font="default" size="100%">Johan HJ Reimerink</style></author><author><style face="normal" font="default" size="100%">Fiona Brouwer</style></author><author><style face="normal" font="default" size="100%">Marieke Hoogerwerf</style></author><author><style face="normal" font="default" size="100%">Chantal BEM Reusken</style></author><author><style face="normal" font="default" size="100%">Gunnveig Grodeland</style></author><author><style face="normal" font="default" size="100%">Sophie Le Cam</style></author><author><style face="normal" font="default" size="100%">Pierre Gallian</style></author><author><style face="normal" font="default" size="100%">Amroun, Abdennour</style></author><author><style face="normal" font="default" size="100%">Nadège Brisbarre</style></author><author><style face="normal" font="default" size="100%">Christophe Martinaud</style></author><author><style face="normal" font="default" size="100%">Isabelle Leparc Goffart</style></author><author><style face="normal" font="default" size="100%">Hubert Schrezenmeier</style></author><author><style face="normal" font="default" size="100%">Hendrik B Feys</style></author><author><style face="normal" font="default" size="100%">Ellen C van der Schoot</style></author><author><style face="normal" font="default" size="100%">Heli Harvala</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data.</style></title><secondary-title><style face="normal" font="default" size="100%">Euro Surveill</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Antibodies, Neutralizing</style></keyword><keyword><style  face="normal" font="default" size="100%">Antibodies, Viral</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Europe</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunization, Passive</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021 07</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">26</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;We compared the performance of SARS-CoV-2 neutralising antibody testing between 12 European laboratories involved in convalescent plasma trials. Raw titres differed almost 100-fold differences between laboratories when blind-testing 15 plasma samples. Calibration of titres in relation to the reference reagent and standard curve obtained by testing a dilution series reduced the inter-laboratory variability ca 10-fold. The harmonisation of neutralising antibody quantification is a vital step towards determining the protective and therapeutic levels of neutralising antibodies.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">27</style></issue></record></records></xml>